AbCellera Biologics (ABCL) Receivables - Other (2020 - 2021)

AbCellera Biologics (ABCL) posted Receivables - Other of $62.1 million for Q2 2021, down 67.84% on a QoQ basis from $193.1 million in Q1 2021.

AbCellera Biologics (ABCL) Receivables - Other (2020 - 2021) Analysis & Trends

AbCellera Biologics' Receivables - Other history runs 2 years deep, the most recent figure standing at $62.1 million for Q2 2021.

Quarterly Receivables - Other changed N/A year-over-year to $62.1 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $62.1 million (changed N/A YoY) and the FY2020 annual result came in at $212.3 million, changed N/A from the prior year.
Receivables - Other was $62.1 million for Q2 2021 at AbCellera Biologics, down from $193.1 million in the prior quarter.
Across five years, Receivables - Other topped out at $212.3 million in Q4 2020 and bottomed at $62.1 million in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	AbCellera Biologics	1.72 Bn	1.72 Bn	-

Download Data